Tocilizumab cost effective in reducing COVID-19-related deaths.
出版信息
PharmacoEcon Outcomes News. 2021;879(1):28. doi: 10.1007/s40274-021-7751-7. Epub 2021 May 29.
Abstract
摘要
相似文献
1
Tocilizumab cost effective in reducing COVID-19-related deaths.托珠单抗在降低新冠肺炎相关死亡方面具有成本效益。
PharmacoEcon Outcomes News. 2021;879(1):28. doi: 10.1007/s40274-021-7751-7. Epub 2021 May 29.
2
Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients.托珠单抗治疗重型和危重型新型冠状病毒肺炎患者的临床疗效
World J Clin Cases. 2020 Sep 6;8(17):3763-3773. doi: 10.12998/wjcc.v8.i17.3763.
3
Impact of tocilizumab administration on mortality in severe COVID-19.托珠单抗治疗对重症 COVID-19 患者死亡率的影响。
Sci Rep. 2020 Nov 5;10(1):19131. doi: 10.1038/s41598-020-76187-y.
4
Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study.托珠单抗治疗重症新型冠状病毒肺炎住院患者的疗效：一项病例对照队列研究。
Pharmaceuticals (Basel). 2020 Oct 17;13(10):317. doi: 10.3390/ph13100317.
5
Tocilizumab and liver injury in patients with COVID-19.托珠单抗与新冠病毒肺炎患者的肝损伤
Therap Adv Gastroenterol. 2020 Oct 7;13:1756284820959183. doi: 10.1177/1756284820959183. eCollection 2020.
6
The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data.托珠单抗在新冠病毒病患者中的作用：基于蒙扎队列数据的思考
Infect Drug Resist. 2021 Apr 13;14:1389-1392. doi: 10.2147/IDR.S304414. eCollection 2021.
7
Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.阿达木单抗、依那西普和托珠单抗作为中重度类风湿关节炎一线治疗药物的成本效益分析。
J Med Econ. 2012;15(2):340-51. doi: 10.3111/13696998.2011.649327. Epub 2012 Jan 6.
8
Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?托珠单抗用于新冠肺炎患者：是灭火之水还是助燃汽油？
Med Mycol Case Rep. 2021 Mar;31:32-34. doi: 10.1016/j.mmcr.2021.01.002. Epub 2021 Jan 21.
9
First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia.托珠单抗在一组因重症 COVID-19 肺炎住院的拉丁美洲患者中的应用首次报告
Front Med (Lausanne). 2020 Nov 16;7:596916. doi: 10.3389/fmed.2020.596916. eCollection 2020.
10
Tocilizumab and COVID-19.托珠单抗与新型冠状病毒肺炎
Indian J Crit Care Med. 2020 Sep;24(9):741-743. doi: 10.5005/jp-journals-10071-23608.
引用本文的文献
1
Countering COVID-19 Vaccine Hesitancy in Pregnancy: the "4 Cs".应对孕期 COVID-19 疫苗犹豫：“4C”原则。
Am J Perinatol. 2022 Jul;39(10):1048-1054. doi: 10.1055/a-1673-5546. Epub 2021 Oct 19.
本文引用的文献
1
Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality.托珠单抗联合地塞米松的成本效益治疗可降低 COVID-19 死亡率。
Clin Infect Dis. 2021 Dec 6;73(11):2116-2118. doi: 10.1093/cid/ciab409.
Zotero 插件